查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370929

儿科药物市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按类型、给药途径、最终用户、地区、竞争细分

Pediatric Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Route Of Administration, By End-User, By Region, By Competition
出版日期: | 出版商: TechSci Research | 英文 178 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年，全球儿科药品市场估值达到1,185.4亿美元，在整个预测期内有望实现令人印象深刻的成长，预计到2028年复合年增长率（CAGR）为5.71%，预计将达到1,650.2亿美元到2028 年。儿科药品市场是製药业的关键部门，专注于为婴儿、儿童和青少年提供安全有效的治疗。满足年轻人的医疗保健需求需要根据他们独特的生理和发育需求量身定制专门的药物。随着医学研究的进步、监管倡议以及对解决儿童健康问题重要性的日益认识的推动，儿科药物市场经历了大幅增长。

美国食品药物管理局（FDA）和欧洲药品管理局（EMA）等监管机构透过延长独占权和经济奖励等激励措施，鼓励製药公司投资儿科药物开发。这些倡议引发了针对儿科族群的更多研发 (R&D) 努力。慢性疾病（例如气喘、糖尿病、神经系统疾病）和传染病（例如 COVID-19）等疾病迫使製药公司专注于针对这些健康挑战的客製化疗法。

基因组学、药理学和药物传递方面的科学进步促进了更精确和个性化的儿科药物的配製，从而促使增加对适合儿童的创新製剂的投资。在监管推动、科学进步以及对儿童独特医疗保健先决条件的认识增强的推动下，儿科药品市场持续发展。

市场概况
预测期 2024-2028
2022 年市场规模 1185.4亿美元
2028 年市场规模 1650.2亿美元
2023-2028 年复合年增长率 5.71%
成长最快的细分市场 网路药局
最大的市场 北美洲

主要市场驱动因素

儿童人口不断增加

人口结构正在发生变化，儿科人口显着增加。根据联合国预测，到 2050 年，全球 0-14 岁人口预计将达到 22 亿。这种激增凸显了对儿科医疗保健的高度关注，推动了对儿童药物的需求。他们独特的生理学需要优先考虑安全性和有效性的专门治疗。

儿科疾病发生率增加

虽然医学的进步降低了儿童死亡率，但慢性病和罕见疾病的盛行率却在上升。儿童癌症、自体免疫疾病、先天性疾病和精神健康障碍等疾病更为明显，需要量身订做的医疗关注和治疗。

主要市场挑战

道德和安全考虑

由于儿童的脆弱性和症状表达的潜在困难，进行涉及未成年人的临床试验需要仔细的伦理指导。平衡资料收集和参与者的福祉是一个挑战。

缺乏研发重点

从历史上看，由于伦理问题和后勤复杂性，儿童在临床试验中的代表性不足。这种稀缺性阻碍了针对儿童需求而设计的有证据支持的治疗的可用性。

剂量和配方的复杂性

与成人相比，儿科患者的动态生长需要不同的剂量方法和药物形式。开发适合年龄的剂型和剂量对于避免不正确的给药结果是复杂且至关重要的。

主要市场趋势

技术进步

技术突破正在重塑儿科医学，改变诊断、治疗和药物开发模式。精准医学、药物基因组学、数位健康技术和人工智慧 (AI) 透过增强治疗客製化、真实世界证据收集和药物发现正在彻底改变儿科医疗保健。

细分市场洞察

类型洞察

呼吸系统疾病药物部分是主要部分，反映了儿科族群中气喘和支气管炎等疾病的盛行率。越来越多的人接触过敏原、感染和环境因素，导致呼吸系统疾病日益突出。

最终用途见解

医院因其在提供客製化儿科护理方面的专业知识而成为主要的最终用户。专业科室和诊断工具使医院成为综合儿科治疗的主要来源。

区域洞察

北美凭藉其强大的製药业、研究机构和有利的监管框架，推动了儿科药物市场的发展。 《儿科研究公平法案》(PREA) 和临床试验基础设施等措施有助于促进成长。

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：COVID-19 对全球儿科药物市场的影响

第 4 章：客户之声

第 5 章：执行摘要

第 6 章：全球噬菌体治疗市场概述

第 7 章：全球儿科药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依类型（呼吸系统疾病药物、自体免疫疾病药物、胃肠道药物、心血管药物）
    • 依给药途径（口服、局部、肠外、其他）
    • 按最终使用者（医院、专科诊所、居家照护）
    • 按公司划分 (2022)
    • 按地区
  • 市场地图
    • 按类型
    • 依给药途径
    • 按最终用户

第 8 章：北美儿科药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • 政策和监管环境
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：欧洲儿科药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • 政策和监管环境
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 10 章：亚太地区儿科药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • 政策和监管环境
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 11 章：南美洲儿科药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 给药途径
    • 按最终用户
    • 按国家/地区
  • 政策和监管环境
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 12 章：中东和非洲儿科药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • 政策和监管环境
  • MEA：国家分析
    • 南非 儿科药物
    • 沙乌地阿拉伯 儿科药物
    • 阿联酋儿科药物

第 13 章：市场动态

  • 司机
  • 挑战

第 14 章：市场趋势与发展

第15章：波特五力分析

第 16 章：全球儿科药物市场：SWOT 分析

第 17 章：用于动物健康的市售噬菌体类型列表

第18章：竞争格局

  • 商业概览
  • 公司概况
  • 类型和服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • BioMarin
    • Horizon Therapeutics plc
    • Gilead Sciences Inc.
    • Sumitomo Pharma Co., Ltd.
    • Jazz Pharmaceuticals, Inc.
    • GlaxoSmithKline plc.
    • Abbott
    • F. Hoffman La Roche, Ltd.
    • Boehringer Ingelheim International GmbH
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Pfizer, Inc.

第 19 章：策略建议

第 20 章：关于我们与免责声明

简介目录
Product Code: 15921

The Global Pediatric Drugs Market reached a valuation of USD 118.54 Billion in 2022, and it is poised for impressive growth throughout the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 5.71% up to 2028 and expected to reach USD 165.02 Billion by 2028. The pediatric drugs market represents a critical sector within the pharmaceutical industry, focused on delivering safe and efficacious treatments for infants, children, and adolescents. Meeting the healthcare needs of the younger demographic necessitates specialized medications tailored to their unique physiological and developmental requirements. The market for pediatric drugs has experienced substantial growth over time, driven by advancements in medical research, regulatory initiatives, and an increased recognition of the significance of addressing childhood health concerns.

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have encouraged pharmaceutical enterprises to invest in pediatric drug development through incentives like exclusivity extensions and financial rewards. These initiatives have sparked heightened research and development (R&D) endeavors directed at pediatric populations. Conditions such as chronic ailments (e.g., asthma, diabetes, neurological disorders) and infectious diseases (e.g., COVID-19) have impelled pharmaceutical companies to concentrate on tailored therapies for these health challenges.

Scientific progress in genomics, pharmacology, and drug delivery has facilitated the formulation of more precise and individualized pediatric medications, thus prompting augmented investment in innovative formulations suitable for children. The pediatric drugs market's evolution persists, buoyed by regulatory drives, scientific advancements, and an enhanced awareness of the distinctive healthcare prerequisites of children.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 118.54 Billion
Market Size 2028USD 165.02 Billion
CAGR 2023-20285.71%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Key Market Drivers

Rising Pediatric Population

The demographic landscape is witnessing a shift, with a notable rise in the pediatric population. By 2050, the global population aged 0-14 is projected to reach 2.2 billion according to the United Nations. This surge underscores the heightened focus on pediatric healthcare, driving the demand for medications tailored to children. Their unique physiology necessitates specialized treatments that prioritize safety and efficacy.

Increasing Incidence of Pediatric Diseases

While advancements in medicine have led to reduced mortality rates among children, the prevalence of chronic and rare diseases has escalated. Conditions such as childhood cancers, autoimmune disorders, congenital diseases, and mental health disorders are more pronounced, compelling tailored medical attention and therapies.

Key Market Challenges

Ethical and Safety Considerations

Conducting clinical trials involving minors requires careful ethical navigation due to children's vulnerability and potential difficulties in symptom expression. Balancing data acquisition and participant well-being poses a challenge.

Lack of R&D Focus

Historically, children have been underrepresented in clinical trials due to ethical concerns and logistical complexities. This scarcity impedes the availability of evidence-backed treatments designed for children's needs.

Dosing and Formulation Complexity

Pediatric patients' dynamic growth necessitates distinct approaches to dosing and drug forms compared to adults. Developing age-appropriate dosage forms and dosages is intricate and crucial to avoid incorrect dosing outcomes.

Key Market Trends

Technological Advancements

Technological breakthroughs are reshaping pediatric medicine, altering diagnosis, treatment, and drug development landscapes. Precision medicine, pharmacogenomics, digital health technologies, and artificial intelligence (AI) are revolutionizing pediatric healthcare by enhancing treatment customization, real-world evidence collection, and drug discovery.

Segmental Insights

Type Insights

The Respiratory Disorder Drugs segment is the dominant segment, reflecting the prevalence of conditions like asthma and bronchitis in pediatric populations. The rising exposure to allergens, infections, and environmental factors contributes to respiratory disorders' prominence.

End-Use Insights

Hospitals are the major end-users due to their expertise in offering tailored pediatric care. Specialized departments and diagnostic tools position hospitals as the primary source of comprehensive pediatric treatment.

Regional Insights

North America, with its robust pharmaceutical industry, research institutions, and favorable regulatory framework, drives the pediatric drugs market. Initiatives like the Pediatric Research Equity Act (PREA) and clinical trial infrastructure contribute to growth.

The forecasted period presents opportunities for growth and innovation in the pediatric drugs market. The industry's response to ethical concerns, formulation complexity, and unique pediatric needs, coupled with advancements in precision medicine, digital health, collaboration, and rare disease treatment, can shape the future of pediatric healthcare positively. By embracing these challenges and capitalizing on opportunities, the pharmaceutical sector can contribute significantly to pediatric well-being and healthcare advancement.

Key Market Players

  • BioMarin
  • Horizon Therapeutics plc
  • Gilead Sciences Inc.
  • Sumitomo Pharma Co., Ltd.
  • Jazz Pharmaceuticals, Inc.
  • GlaxoSmithKline plc.
  • Abbott
  • F. Hoffman La Roche, Ltd.
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer, Inc.

Report Scope:

  • In this report, the Global Pediatric Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Pediatric Drugs Market, By Type:

  • Respiratory Disorder Drugs
  • Autoimmune Disorder Drugs
  • Gastrointestinal Drugs
  • Cardiovascular Drugs

Pediatric Drugs Market, By Route Of Administration:

  • Oral
  • Topical
  • Parenteral
  • Others

Pediatric Drugs Market, By End-Use:

  • Hospitals
  • Specialty Clinics
  • Homecare

Pediatric Drugs Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Drugs Market.

Available Customizations:

  • Global Pediatric Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Pediatric Drugs Market

4. Voice of Customer

5. Executive Summary

6. Global Phage Therapy Market Overview

7. Global Pediatric Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs)
    • 7.2.2. By Route Of Administration (Oral, Topical, Parenteral, Others)
    • 7.2.3. By End User (Hospitals, Specialty Clinics, Homecare)
    • 7.2.4. By Company (2022)
    • 7.2.5. By Region
  • 7.3. Market Map
    • 7.3.1. By Type
    • 7.3.2. By Route Of Administration
    • 7.3.3. By End User

8. North America Pediatric Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Route Of Administration
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Policy & Regulatory Landscape
  • 8.4. North America: Country Analysis
    • 8.4.1. United States Pediatric Drugs Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Type
        • 8.4.1.2.2. By Route Of Administration
        • 8.4.1.2.3. By End User
    • 8.4.2. Mexico Pediatric Drugs Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Type
        • 8.4.2.2.2. By Route Of Administration
        • 8.4.2.2.3. By End User
    • 8.4.3. Canada Pediatric Drugs Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Type
        • 8.4.3.2.2. By Route Of Administration
        • 8.4.3.2.3. By End User

9. Europe Pediatric Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route Of Administration
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Policy & Regulatory Landscape
  • 9.4. Europe: Country Analysis
    • 9.4.1. France Pediatric Drugs Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Type
        • 9.4.1.2.2. By Route Of Administration
        • 9.4.1.2.3. By End User
    • 9.4.2. Germany Pediatric Drugs Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Type
        • 9.4.2.2.2. By Route Of Administration
        • 9.4.2.2.3. By End User
    • 9.4.3. United Kingdom Pediatric Drugs Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Type
        • 9.4.3.2.2. By Route Of Administration
        • 9.4.3.2.3. By End User
    • 9.4.4. Italy Pediatric Drugs Market Outlook
      • 9.4.4.1. Market Size & Forecast
        • 9.4.4.1.1. By Value
      • 9.4.4.2. Market Share & Forecast
        • 9.4.4.2.1. By Type
        • 9.4.4.2.2. By Route Of Administration
        • 9.4.4.2.3. By End User
    • 9.4.5. Spain Pediatric Drugs Market Outlook
      • 9.4.5.1. Market Size & Forecast
        • 9.4.5.1.1. By Value
      • 9.4.5.2. Market Share & Forecast
        • 9.4.5.2.1. By Type
        • 9.4.5.2.2. By Route Of Administration
        • 9.4.5.2.3. By End User

10. Asia-Pacific Pediatric Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route Of Administration
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. Policy & Regulatory Landscape
  • 10.4. Asia-Pacific: Country Analysis
    • 10.4.1. China Pediatric Drugs Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Type
        • 10.4.1.2.2. By Route Of Administration
        • 10.4.1.2.3. By End User
    • 10.4.2. India Pediatric Drugs Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Type
        • 10.4.2.2.2. By Route Of Administration
        • 10.4.2.2.3. By End User
    • 10.4.3. Japan Pediatric Drugs Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Type
        • 10.4.3.2.2. By Route Of Administration
        • 10.4.3.2.3. By End User
    • 10.4.4. South Korea Pediatric Drugs Market Outlook
      • 10.4.4.1. Market Size & Forecast
        • 10.4.4.1.1. By Value
      • 10.4.4.2. Market Share & Forecast
        • 10.4.4.2.1. By Type
        • 10.4.4.2.2. By Route Of Administration
        • 10.4.4.2.3. By End User
    • 10.4.5. Australia Pediatric Drugs Market Outlook
      • 10.4.5.1. Market Size & Forecast
        • 10.4.5.1.1. By Value
      • 10.4.5.2. Market Share & Forecast
        • 10.4.5.2.1. By Type
        • 10.4.5.2.2. By Route Of Administration
        • 10.4.5.2.3. By End User

11. South America Pediatric Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. Route Of Administration
    • 11.2.3. By End User
    • 11.2.4. By Country
  • 11.3. Policy & Regulatory Landscape
  • 11.4. South America: Country Analysis
    • 11.4.1. Brazil Pediatric Drugs Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Type
        • 11.4.1.2.2. By Route Of Administration
        • 11.4.1.2.3. By End User
    • 11.4.2. Argentina Pediatric Drugs Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Type
        • 11.4.2.2.2. By Route Of Administration
        • 11.4.2.2.3. By End User
    • 11.4.3. Colombia Pediatric Drugs Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Type
        • 11.4.3.2.2. By Route Of Administration
        • 11.4.3.2.3. By End User

12. Middle East and Africa Pediatric Drugs Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By Route Of Administration
    • 12.2.3. By End User
    • 12.2.4. By Country
  • 12.3. Policy & Regulatory Landscape
  • 12.4. MEA: Country Analysis
    • 12.4.1. South Africa Pediatric Drugs Market Outlook
      • 12.4.1.1. Market Size & Forecast
        • 12.4.1.1.1. By Value
      • 12.4.1.2. Market Share & Forecast
        • 12.4.1.2.1. By Type
        • 12.4.1.2.2. Route Of Administration
        • 12.4.1.2.3. By End User
    • 12.4.2. Saudi Arabia Pediatric Drugs Market Outlook
      • 12.4.2.1. Market Size & Forecast
        • 12.4.2.1.1. By Value
      • 12.4.2.2. Market Share & Forecast
        • 12.4.2.2.1. By Type
        • 12.4.2.2.2. By Route Of Administration
        • 12.4.2.2.3. By End User
    • 12.4.3. UAE Pediatric Drugs Market Outlook
      • 12.4.3.1. Market Size & Forecast
        • 12.4.3.1.1. By Value
      • 12.4.3.2. Market Share & Forecast
        • 12.4.3.2.1. By Type
        • 12.4.3.2.2. By Route Of Administration
        • 12.4.3.2.3. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Porter's Five Force's Analysis

16. Global Pediatric Drugs Market: SWOT Analysis

17. List of Commercially Available Phage Types for Animal Health

18. Competitive Landscape

  • 18.1. Business Overview
  • 18.2. Company Snapshot
  • 18.3. Types & Services
  • 18.4. Financials (In case of listed companies)
  • 18.5. Recent Developments
  • 18.6. SWOT Analysis
    • 18.6.1. BioMarin
    • 18.6.2. Horizon Therapeutics plc
    • 18.6.3. Gilead Sciences Inc.
    • 18.6.4. Sumitomo Pharma Co., Ltd.
    • 18.6.5. Jazz Pharmaceuticals, Inc.
    • 18.6.6. GlaxoSmithKline plc.
    • 18.6.7. Abbott
    • 18.6.8. F. Hoffman La Roche, Ltd.
    • 18.6.9. Boehringer Ingelheim International GmbH
    • 18.6.10. Johnson & Johnson Services, Inc.
    • 18.6.11. Novartis AG
    • 18.6.12. Pfizer, Inc.

19. Strategic Recommendations

20. About Us & Disclaimer